Onyx, MD Anderson Team Up to Fight Lymphoma and Myeloma

MD-anderson-cancer-center-logo.jpg

Onyx Pharmaceuticals, Inc and the University of Texas MD Anderson Cancer Center have announced a
non-exclusive two year alliance for pre-clinical and clinical research to continue to understand the role that novel experimental therapies, specifically but not limited to Onyx's carfilzomib and oprozomib, can play in multiple myeloma and lymphoma.

The greater goal will be to contribute to the biological understanding and clinical profile of carfilzomib and oprozomib in the treatment of both myeloma and lymphomas. The potential for combining proteasome inhibitors with other novel therapies currently in earlier stages of development will be an important component of this collaboration.

Christopher J. Kirk, Ph.D., Vice President, Research at Onyx Pharmaceuticals:

"MD Anderson Cancer Center is a recognized world leader in the development of new therapies for the treatment of patients with hematologic malignancies. This agreement underscores the importance of academic and industry alliances as one of the most important types of public-private collaborations. Onyx is committed to exploring ways in which these types of alliances can advance the development of potential lifesaving drugs and new treatments for patients."

Dr. Robert Orlowski, Professor, Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center:

"MD Anderson and Onyx have a shared vision of developing innovative therapies for improving the lives of people with cancer. This alliance is designed to accelerate the discovery and translation of new knowledge about cancer from the laboratory, to the clinic, and, ultimately, to the patients."

Source: MarketWatch

LymphomaInfo Social